Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) rose 1.9% during trading on Tuesday . The stock traded as high as $2.15 and last traded at $2.11, with a volume of 369,017 shares changing hands. The stock had previously closed at $2.07.

AUPH has been the subject of several analyst reports. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. HC Wainwright initiated coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 price target for the company. Leerink Swann reissued an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $7.75.

The company’s market capitalization is $74.81 million. The company’s 50-day moving average is $2.51 and its 200 day moving average is $2.75.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp boosted its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned about 0.29% of Aurinia Pharmaceuticals worth $283,000 as of its most recent filing with the SEC. 20.04% of the stock is owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.